The DEA Supply-Chain Fight Reaches Court
Emergency relief, late applications, and pressure on existing trading relationships.
Questions? Message me or call/text 916-572-6445
The November 29 supply-chain transition is now at the center of a court challenge. This week’s articles examine the emergency stay request, what a late application can accomplish, and why businesses that never applied may still be affected.
TLDR:
Two groups of cannabis businesses filed court challenges this week seeking to pause the DEA’s supply-chain restrictions while their cases proceed. The cases put existing trading relationships, application timing, and the future of the federal medical market in focus.
Watch the Issue 12 video
Watch the captioned overview above, or open it on YouTube.
The supply-chain restrictions are being challenged in court
On November 18, Standard Wellness Utah, Verde Americano, and NW Confections OK 241AA filed an emergency motion in the D.C. Circuit. They asked the court to stay the DEA’s October 30 guidance while their challenge proceeds, with a ruling or temporary administrative stay requested by November 25.
The immediate motion seeks a pause in the guidance’s operation pending judicial review. Their underlying arguments seek to have the challenged action set aside.
The companies argue that the guidance conflicts with the April rule’s treatment of timely applicants, imposes binding restrictions without required procedures, and fails to account for the disruption to existing state markets. They project lost sales, layoffs, and supply problems in their filing.
Read: Cannabis Businesses Challenge the DEA’s Supply-Chain Restrictions, Seek Emergency Stay
A November 20 Marijuana Moment report identifies a second challenge by Pennsylvania operators and reports that the cases have been consolidated. Those operators say their manufacturing operations could be barred from supplying their own dispensaries because the manufacturing operations lack timely-applicant status.
What the November 29 guidance addresses
Paragraph 11 of the DEA’s guidance says timely applicants are expected to finish verifying trading partners, make necessary supply-chain adjustments, and establish compliant supply chains by November 29. Paragraph 8 calls for both timely applicants and registrants to confirm counterparties’ status and retain diligence records.
The guidance separately permits Timely Dispenser Applicants and Timely Distributor Applicants to continue possessing, dispensing, and distributing covered existing inventory acquired before the guidance was issued, in otherwise authorized activities.
Late applications and the direction of the market
This week’s late-application article examines the path available to businesses that missed the initial window. Under the DEA’s guidance, a business outside the qualifying timely-applicant group needs the appropriate registration before participating in covered transactions with timely applicants or registrants.
The analysis includes whether approval is realistically available, what the DEA is objecting to in the relevant jurisdiction, and what operating changes might be required. Those questions affect the time and money a business could commit to an application or restructuring.
The possibility of a market increasingly organized around federal medical participation also belongs in that analysis. So does the direction of federal enforcement. What will enforcement look like as this system develops, and how should that exposure inform whether a business starts the application process now, even after missing the timely-applicant window?
Read: I Missed the DEA’s Timely-Applicant Window. Should I Still Apply?
Nonapplicants are part of the same supply chain
A business that never applied can still lose a customer whose federal status changes the suppliers it can use. A manufacturer may need different inputs. A retailer may need different products. Those pressures can reach businesses that viewed federal registration as somebody else’s issue.
Reviewing those relationships is useful preparation. So is documenting what has been verified, what remains uncertain, and which transactions or activities require further analysis.
Read: Didn’t Apply for DEA Registration? Your Supply Chain May Still Be at Stake
My concern is the cost of making a major decision around an assumed solution. Before surrendering a license or reorganizing an operation, a business needs to understand which problem the change would address and which objections would remain. But there is another side to that calculation: what choices will businesses realistically have if federal enforcement intensifies? The cost of applying or restructuring has to be weighed alongside the exposure associated with continuing current operations.
This week’s filings bring the immediate supply-chain dispute before the court. The broader question is how businesses will operate as the federal medical market develops, and how enforcement will shape the choices available to them.
Thanks for reading,
Ryan
Attorney Advertising. General information, not legal advice. Reading this issue or contacting the firm does not create an attorney-client relationship.
